JP2012097034A5 - - Google Patents

Download PDF

Info

Publication number
JP2012097034A5
JP2012097034A5 JP2010246112A JP2010246112A JP2012097034A5 JP 2012097034 A5 JP2012097034 A5 JP 2012097034A5 JP 2010246112 A JP2010246112 A JP 2010246112A JP 2010246112 A JP2010246112 A JP 2010246112A JP 2012097034 A5 JP2012097034 A5 JP 2012097034A5
Authority
JP
Japan
Prior art keywords
composition
hipokisanchi
autoinducer
creatine
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010246112A
Other languages
English (en)
Japanese (ja)
Other versions
JP5756614B2 (ja
JP2012097034A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2010246112A priority Critical patent/JP5756614B2/ja
Priority claimed from JP2010246112A external-priority patent/JP5756614B2/ja
Publication of JP2012097034A publication Critical patent/JP2012097034A/ja
Publication of JP2012097034A5 publication Critical patent/JP2012097034A5/ja
Application granted granted Critical
Publication of JP5756614B2 publication Critical patent/JP5756614B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010246112A 2010-11-02 2010-11-02 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤 Expired - Fee Related JP5756614B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010246112A JP5756614B2 (ja) 2010-11-02 2010-11-02 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010246112A JP5756614B2 (ja) 2010-11-02 2010-11-02 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤

Publications (3)

Publication Number Publication Date
JP2012097034A JP2012097034A (ja) 2012-05-24
JP2012097034A5 true JP2012097034A5 (enExample) 2013-10-31
JP5756614B2 JP5756614B2 (ja) 2015-07-29

Family

ID=46389377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010246112A Expired - Fee Related JP5756614B2 (ja) 2010-11-02 2010-11-02 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤

Country Status (1)

Country Link
JP (1) JP5756614B2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2745836B1 (en) * 2012-12-18 2016-08-31 Sunstar Suisse SA Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers
EP3405193B1 (en) * 2016-01-19 2022-03-23 AchromaZ Pte. Ltd. A cosmetic composition and the use thereof for regulating skin quality
CN108042384B (zh) * 2018-01-08 2020-07-10 弘美制药（中国）有限公司 一种具有口腔清洁和治疗功效的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338712C (en) * 1998-07-28 2012-10-09 Synergen Ag Use of creatine compounds for treatment of bone or cartilage cells and tissues
DE19841385A1 (de) * 1998-09-10 2000-03-16 Sueddeutsche Kalkstickstoff Verwendung von Kreatin und/oder Kreatin-derivaten als Feuchthaltemittel in kosmetischen Zubereitungen
JP2010159219A (ja) * 2009-01-07 2010-07-22 Kao Corp Ａｉ−２阻害剤

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2015523407A5 (enExample)
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
JP2009537554A5 (enExample)
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
HK1208222A1 (en) Modified release formulations for oprozomib
JP2012508256A5 (enExample)
MX2013005482A (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
JP2007238598A5 (enExample)
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
JP2012097036A5 (enExample)
JP2012097034A5 (enExample)
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
JP2015512948A5 (enExample)